So that was a retrospective analysis that we did within the infectious complications committee of the Spanish transplant group and cellular therapy group. And basically, we were looking at the effect of this third shot in patients with hematological malignancies, both transplant and non-transplant patients that had already gone through COVID-19. The major problem, while there are several problems when talking about COVID-19 infection and immunosuppressed patients, the first one, of course, is the higher mortality that COVID-19 infection has in patients with hematological malignancies...
So that was a retrospective analysis that we did within the infectious complications committee of the Spanish transplant group and cellular therapy group. And basically, we were looking at the effect of this third shot in patients with hematological malignancies, both transplant and non-transplant patients that had already gone through COVID-19. The major problem, while there are several problems when talking about COVID-19 infection and immunosuppressed patients, the first one, of course, is the higher mortality that COVID-19 infection has in patients with hematological malignancies. Another important aspect is the fact that these patients are not as well immunized when they are vaccinated if we compare them with the general population of people. And basically, because of that, the immunological effect that going through COVID-19 infection has in the capacity of the patient to produce antibodies against the virus is still, let’s say, questionable. And because of that, even if in the general population of patients, we make some differences in those that have had COVID-19 infection regarding the next vaccination in immunocompromised patients, this is really important because we cannot take for granted that just because they have been infected, they are immunized against the virus.
